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REGULAR ARTICLE
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Key Points

• The addition of sorafenib to chemotherapy for older adults with
FLT3-ITD mutated AML
is safe and may improve
overall survival.

The Cancer and Leukemia Group B (CALGB), now part of the Alliance for Clinical Trials in
Oncology, conducted a multicenter, single-arm, phase 2 study in patients $60 years with FMSlike tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML). In this study,
sorafenib was added to daunorubicin and cytarabine-based induction and consolidation
chemotherapy and was also continued for 12 months of maintenance therapy. The primary
end point of the study was overall survival (OS) at 1 year in the FLT3 internal tandem
duplication (FLT3-ITD) cohort. Fifty-four patients with a median age of 67 years (range,
60.3-82.7 years) were enrolled; 39 were FLT3-ITD patients (71%) and 15 were FLT3-TKD
(29%) patients. The observed 1-year OS (95% conﬁdence interval [CI]) was 62% (45%-78%)
for the FLT3-ITD patients (meeting the primary end point 62% vs 30% for a historical control
group, P , .0001) and 71% (42%-92%) for the FLT3-TKD patients. The median disease-free
survival and OS were 12.2 months (95% CI, 5-16.9) and 15.0 months (95% CI, 10.4-20.1),
respectively, in the FLT3-ITD group and 9.6 (95% CI, 1.9 to not available [NA]) and 16.2 months
(95% CI, 5.0 to NA) for the FLT3-TKD group. This study suggests that the addition of sorafenib
to chemotherapy for FLT3-ITD AML is feasible and may improve the survival of older adults
with FLT3-mutated AML. This trial was registered at www.clinicaltrials.gov as #NCT01253070.

Introduction
The overall outcome of older adults ($60 years) with acute myeloid leukemia (AML) has changed little
over the past few decades. For patients deemed fit for intensive treatment, induction chemotherapy
combining an anthracycline and cytarabine is associated with a lower rate of complete remission (CR;
50%-60%) and higher early mortality (up to 20% at 30 days) compared with younger patients.1-3
Intensification of postremission therapy with high-dose cytarabine is poorly tolerated and has not
improved outcomes, with a 3-year disease-free survival (DFS) of ;10% to 15%.4 The reasons for
increased toxicity and decreased survival are incompletely understood and include both unfavorable
tumor biology and patient-specific characteristics such as increased comorbidities.
FMS-like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase expressed on both normal CD341
hematopoietic stem and progenitor cells and AML blasts. Mutations of FLT3 are common in AML,
occurring in 20% to 30% of adult patients across the entire age spectrum.2 These mutations occur
either as an internal tandem duplication (ITD) of the juxtamembrane domain or as a point mutation in the
Submitted 18 November 2016; accepted 21 December 2016. DOI 10.1182/
bloodadvances.2016003053.
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activation loop of the tyrosine kinase domain (TKD), both of which
result in ligand-independent activation and signaling that stimulate the proliferation of AML blasts.5-8 The presence of an FLT3
mutation is associated with a poor prognosis in AML, with an
increased rate of relapse and reduced OS.7,9-12 In earlier prospective studies by the Cancer and Leukemia Group B (CALGB;
now a part of the Alliance for Clinical Trials in Oncology) analyzing
outcomes for 219 previously untreated adults $60 years with AML
treated with chemotherapy alone, the CR rate for the 72 patients
with an FLT3-ITD was 67%, compared with 70% for the 147 with
wild-type FLT3 (FLT3-WT).13 However, overall outcomes were
markedly different. After 1 year, overall survival (OS) was 31% vs
69%, event-free survival (EFS) was 17% vs 40%, and DFS was
25% vs 53% for patients with FLT3-ITD vs FLT3-WT. FLT3 is
therefore an attractive target in AML, and several FLT3 inhibitors are
currently in clinical development, including midostaurin, quizartinib,
and gilteritinib.14,15
Sorafenib (Nexavar) is an oral multikinase inhibitor approved for the
treatment of metastatic renal cell and advanced hepatocellular
carcinoma.16,17 Sorafenib was initially developed as an inhibitor of
RAF1, a serine-threonine kinase in the mitogen activated protein
kinase (MAPK) pathway critical in cellular responses such as cell
proliferation, growth, motility, survival, and apoptosis. Sorafenib is a
potent inhibitor of the FLT3-ITD, with a 50% inhibitory concentration
in the single-digit nanomolar range.18 Although FLT3-TKD mutations
are resistant to sorafenib,19 sorafenib blocks the autophosphorylation
and activation of other tyrosine kinases, including vascular endothelial
growth factor, platelet-derived growth factor receptor B, FGFR1, and
KIT. Furthermore, inhibition of the MAPK pathway by sorafenib may
also contribute to its clinical activity, as MAPK is a downstream target
of FLT3 signaling and can be activated by other factors, including
mutations in RAS, which are found in ;15% of patients with AML.
Sorafenib has been tested as a single agent in phase 1 clinical trials
for patients with relapsed or refractory AML. Evidence of clinical
activity was observed, with CR or complete remission with incomplete
hematopoietic recovery (CRi) achieved in 5 (10%) patients and a
significant reduction in bone marrow and/or peripheral blood blasts in
17 (34%) additional patients, all of whom had FLT3-ITD mutations.20
Sorafenib has also been tested as a single agent in the compassionate use setting, with case series reporting the development of rapid
remissions in patients with FLT3-ITD–mutated relapsed or refractory
disease.21,22 Responses were transient, however, with no durable
remissions reported. Sorafenib has also been used in combination
with idarubicin and cytarabine. In a phase 2 trial, 18 patients with
newly diagnosed AML with FLT3-ITD were treated with this regimen,
with 17 out of 18 patients (94%) achieving a morphological CR/
complete remission with incomplete platelet recovery.23 Phase 3
studies have combined sorafenib with chemotherapy for younger and
older adults with AML, with mixed results.24,25 We hypothesized
that the addition of sorafenib to induction and postremission
therapy in patients .60 years with FLT3-mutated AML would
improve the OS of these patients.

Subjects and methods
Description of participants
This CALGB trial (registered at www.clinicaltrials.gov as
#NCT01253070) was conducted as a multicenter, single-arm
phase 2 study. Eligible subjects were age $60 years, diagnosed
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with AML with a FLT3 mutation, and had no prior chemotherapy for
their disease. Subjects with acute promyelocytic leukemia, AML
with t(8;21)(q22;q22), RUNXT-RUNX1T1, or inv(16)(p13.1q22),
CBFB-MYH11 were excluded from the study. Patients with a history
of a myelodysplastic syndrome or myeloproliferative neoplasm were
eligible provided that they had not received chemotherapy including
lenalidomide, azacitidine, or decitabine for their antecedent hematologic disorder. Institutional review board approval was obtained for
the study by all participating institutions.

Treatment plan
Remission induction therapy consisted of 713 (cytarabine 100 mg/m2
per day by continuous intravenous infusion on days 1-7 and
daunorubicin 60 mg/m2 per day IV on days 1-3) with sorafenib
400 mg orally every 12 hours on days 1 to 7. A second induction
course consisting of 512 with sorafenib (cytarabine 100 mg/m2 per
day on days 1-5, daunorubicin 60 mg/m2 per day on days 1-2, and
sorafenib 400 mg twice daily on days 1-7) was administered to
patients not achieving a hypoplastic marrow on a day 114 bone
marrow evaluation. Due to a daunorubicin shortage in the United States
during the study, substitution of idarubicin 12 mg/m2 day was permitted
during induction. Sorafenib for this trial was supplied by the National
Cancer Institute and Bayer Pharmaceuticals, Inc.
For patients achieving a CR or CRi, postremission therapy
consisted of 2 cycles of intermediate-dose cytarabine 2 g/m2 per
day over 3 hours on days 1 to 5, together with sorafenib 400 mg
twice daily for 28 days. Maintenance treatment with sorafenib
400 mg twice daily was then administered for up to twelve 28-day
cycles. No dose modifications were made for hematologic toxicities
during remission induction or consolidation therapy. During maintenance, sorafenib was interrupted and could be dose-reduced for grade
3/4 neutropenia (absolute neutrophil count ,1000/mL), thrombocytopenia (platelets ,50 000/mL), or clinically significant grade 3/4
nonhematologic toxicities. Patients who achieved a CR/CRi were
permitted to undergo an allogeneic hematopoietic cell transplant
(allo-HCT) if deemed appropriate by the treating physician. Response to treatment was assessed according to the Revised
International Working Group criteria for AML.26

FLT3 analysis
Detection of either the FLT3-ITD or TKD (D835) mutation was
performed using standard polymerase chain reaction (PCR) techniques by a Clinical Laboratory Improvement Amendments–
approved central laboratory. Genomic DNA was isolated from cells
submitted to the Alliance Leukemia Tissue Bank at the Ohio State
University using a QIAamp DNA Blood Mini Kit. Exons 14/15 and
exon 20 of FLT3 were simultaneously amplified in triplicate with
primers described previously.27 For the ITD analysis, PCR was
initiated at 95°C for 15 minutes, followed by 35 cycles at 95°C for
30 seconds, 58°C for 55 seconds, 72°C for 90 seconds, and 72°C
for 10 minutes. For the TKD D835 mutation, PCR was initiated at
95°C for 15 minutes, followed by 40 cycles at 95°C for 30 seconds,
58°C for 60 seconds, 72°C for 105 seconds, and 72°C for
10 minutes. The TKD amplicons (5 mL) were subjected to digestion
with 1 U EcoRV (Invitrogen, Carlsbad, CA) in a 20-mL reaction at
37°C for 1 hour, followed by heat activation at 65°C for 10 minutes.
The resultant ITD and EcoRV-digested TKD amplicons were
subjected to capillary electrophoresis in a 3130XL Genetic analyzer
and analyzed by GeneMapper V4.0 (Applied Biosystems, Foster
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Figure 1. FLT3 mutation screening. WT denotes wild-type

Screened for FLT3 Mutation
N=474

alleles.

FLT3 ITD & TKD
N=1

FLT3 ITD
N=62

FLT3 ITD
N=39

City, CA). The lower limit of detection was 2.6% (2.169% 6 0.94%)
and 4.4% (4.384% 6 0.40%) for ITD and TKD, respectively. The
cutoff for ITD and TKD for this clinical trial was 5.0%. The allelic ratio
was defined as FLT3-mutant/FLT3-WT.
Plasma inhibitory assays (PIAs) were performed as previously
described.28 Briefly, Molm-14 cells, which harbor an FLT3-ITD
mutation, were incubated with patient plasma and subjected to
antiphosphotyrosine immunoblotting. Densitometry was performed, and the PIA was calculated by expressing the density as
percent decrease from the baseline pretreatment sample.

Statistical considerations
The trial was designed as a 1-stage single-arm phase 2 study. The
primary end point of the study was the 1-year OS rate in the FLT3ITD AML subgroup. Historically, patients in this subgroup who were
not treated with sorafenib had CR rates of 67% and 1-year OS
rates of 31%.13 The study was designed to detect an improvement
in the 1-year OS rate from 30% to 50% using a 1-sided type I error
rate of 10%. A sample size of 39 evaluable patients with newly
diagnosed FLT3-ITD AML was required based on these assumptions. This sample size also provided 90% power to detect an
improvement in the complete remission rates from 67% to 82%.
OS was defined as the time from registration to death from any
cause. EFS was defined as the time from registration to failure to
achieve CR during induction, relapse after achieving a CR, or death
from any cause. DFS was defined for patients who achieved a
complete response during induction as the time from CR or CRi to
relapse after achieving a CR or CRi or death from any cause. Patients
who were event-free for each time-to-event end point were censored
at their time of last follow-up. All time-to-event end points were
analyzed using the method of Kaplan-Meier. Univariable Cox proportional hazards models for time-to-event end points (OS, DFS, and
EFS) were performed to understand the impact of sex, age, race/
ethnicity, FLT3 status, and European LeukemiaNet classification on
outcomes. All P values reported are 2 sided, except for the primary
efficacy analyses, which are 1 sided following the design of the study.

Results
FLT3 mutation screening
Data were frozen for this analysis as of May 2016. All patients were
off active treatment at the time of this analysis. A total of 474 older
24 JANUARY 2017 x VOLUME 1, NUMBER 5

FLT3 TKD
N=20

FLT3 WT
N=391

Screening
Results

Enrolled,
eligible
patients

FLT3 TKD
N=15

adults were screened for FLT3 mutations through the central
laboratory. The median turn-around time for FLT3 testing from
receipt of sample was 46 hours, and 99.1% of cases were returned
within 48 hours. FLT3 mutations were identified in 83 subjects

Table 1. Baseline characteristics
FLT3 ITD
(n 5 39)

FLT3 TKD
(n 5 15)

Total
(N 5 54)

Age, y
Median (range)
$70

67.6 (60.3-82.7) 65.4 (60.8-82.1) 67.4 (60.3-82.7)
17 (44)

3 (20)

20 (37)

Male

20 (51)

10 (67)

30 (56)

Female

19 (49)

5 (33)

24 (44)

46 (85)

Sex

Onset of AML
De novo

32 (82)

14 (93)

Therapy-related myeloid

2 (5)

1 (7)

3 (6)

MDS related

5 (13)

0 (0)

5 (9)

ELN classification
Intermediate I/CN-AML

21 (54)

6 (40)

27 (50)

Intermediate II

12 (31)

5 (33)

17 (32)

ELN adverse

1 (3)

2 (13)

3 (6)

Cytogenetics insufficient for
evaluation

5 (13)

2 (13)

7 (13)

Allelic ratio
Median (range)

0.7 (0.1-7.3)

0.3 (0.1-2.1)

22 (0.8-344)

16 (0.7-60)

18 (0.7-344)

68 (0-96)

58 (31-96)

60 (0-96)

WBC count
Median (range)
Bone marrow blast, %
Median (range)*
ECOG performance status
0

18 (46)

5 (33)

23 (43)

1

17 (44)

10 (67)

27 (50)

2

4 (10)

0

4 (7)

Data are presented as n (%) of patients unless otherwise indicated.
CN, cytogenetically normal; ECOG, Eastern Cooperative Oncology Group; ELN, European
LeukemiaNet; MDS, myelodysplastic syndrome; WBC, white blood cell.
*One patient was enrolled with multiple myeloid sarcomas but no increase in bone marrow blasts.
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Figure 2. Overall outcomes of FLT3-mutated AML treated

Overall Survival

with sorafenib. Kaplan-Meier curves for OS (A), DFS (B), and
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(17.5%), including 62 (13.1%) with FLT3-ITD, 20 (4.2%) with FLT3TKD, and 1 (0.2%) with both ITD and TKD (Figure 1). Between April
2011 and August 2013, 54 patients (39 with FLT3-ITD and 15 with
FLT3-TKD) enrolled in the study. This study used a common CALGB
screening protocol that enabled patients who were subsequently
considered unsuitable for intensive therapy by their treating
physician to enroll in an alternative CALGB clinical trial.

Patient characteristics
Baseline characteristics are summarized in Table 1. The median age
of the study cohort was 67 years, and 37% of patients (n 5 20)
were $70 years. The majority of patients (85%; n 5 46) had de
novo disease and either normal or intermediate-risk cytogenetics
according to European LeukemiaNet classification.29 The median
FLT3 allelic ratio was 0.7 (range, 0.1-7.3) for patients with FLT3-ITD
and 0.3 (range, 0.1-2.1) for patients with FLT3-TKD.

Remission induction
Following 1 or 2 courses of induction chemotherapy, 74% of
patients (40 of 54) achieved a CR. No patient had a CRi. A total of
31 patients (57%) achieved CR after the first induction course, and
9 (17%) required a second cycle of induction chemotherapy. The
rate of CR was similar between patients with FLT3-ITD (74%; 95%
confidence interval [CI], 58%-87%) and FLT3-TKD (73%;
45%-92%). The CR rate by age categorization was 86% for patients
60 to 69 years (19 of 22) and 59% for those $70 years (10 of 17)
in the FLT3-ITD subgroup; the CR rate was 67% for patients 60 to
69 years (8 of 12) vs 100% for those $70 years (3 of 3) in the
FLT3TKD subgroup. Five deaths (9%) occurred during the initial 30
days of treatment. All early deaths occurred in subjects aged $69
years (range, 69-81 years).

Consolidation and maintenance
Of the 40 patients who achieved a CR, 33 received consolidation
with intermediate-dose cytarabine plus sorafenib. Subsequently,
21 patients (16 with FLT3-ITD and 5 with FLT3-TKD) started maintenance therapy, receiving a median of six 28-day cycles of therapy
(range, 1-12 cycles). During sorafenib maintenance, the most
commonly reported treatment-related adverse events were grade 1
diarrhea, fatigue, and transaminitis and grade 2 palmar-plantar
erythrodysesthesia. Three patients discontinued sorafenib secondary to adverse events (including 2 cases involving a rash).

Survival
With a median follow-up of 34.8 months for surviving patients, the
Kaplan-Meier estimate for median OS was 15 (range, 10.4-20.1)
months for patients with FLT3-ITD and 16.2 (range, 5.0 to not
available [NA]) months for FLT3-TKD (Figure 2A). The observed
1-year OS rate was 62% (95% CI, 45%-78%) in the FLT3-ITD
group and 71% (95% CI, 42%-92%) in the FLT3-TKD group. This
study thus met the protocol-defined criteria for improvement in the
1-year OS rate (62% vs 30% [our historical experience]; 1-sided
P , .0001). The median and 1-year DFS were 12.2 months (95%
CI, 5.0-16.9) and 52% (95% CI, 36%-74%) for FLT3-ITD patients
and 9.6 months (95% CI, 1.9 to NA) and 36% (95% CI, 17%-80%)
for FLT3-TKD patients (Figure 2B). For ITD and TKD patients, the
median EFS was 8.8 months (95% CI, 3.0-13.9) and 7.8 months (95%
CI, 1.3-11.6), respectively, with a 1-year EFS of 39% (95% CI, 26-57)
and 27% (95% CI, 12-62), respectively (Figure 2C). For all subjects,
the 2-year OS and EFS rates were 27% (95% CI, 17%-43%) and
24 JANUARY 2017 x VOLUME 1, NUMBER 5

Table 2. Univariable Cox proportional hazards models for OS, EFS,
and DFS for the FLT3-ITD subgroup
n (events)

HR

95% CI

2-sided
P value

OS
Race/ethnicity (non-Hispanic
white vs other)

39 (29)

0.538 0.226-1.280

.16

Sex (female vs male)

39 (29)

1.289 0.620-2.682

.50

Age ($70 y vs ,70 y)

39 (29)

2.600 1.237-5.469

.01

ELN risk group (CN-AML vs
intermediate II)

34 (24)

1.230 0.504-3.002

.65

ELN risk group (ELN adverse vs
intermediate II)

34 (24)

1.764 0.211-14.782

.60

Allelic ratio ($0.7 vs ,0.7)
(cutoff at median)

39 (29)

1.793 0.845-3.807

.13

39 (32)

0.766 0.327-1.787

.54

EFS
Race/ethnicity (non-Hispanic
white vs other)
Sex (female vs male)

39 (32)

1.338 0.665-2.691

.41

Age ($70 y vs ,70 y)

39 (32)

2.738 1.340-5.596

.01

ELN risk group (CN-AML vs
intermediate II)

34 (27)

1.302 0.565-3.00

.54

ELN risk group (ELN adverse vs
intermediate II)

34 (27)

3.789 0.441-32.554

.22

Allelic ratio ($ 0.7 vs , 0.7)
(cutoff at median)

39 (32)

1.665 0.823-3.366

.16

29 (22)

0.426 0.167-1.082

.07

DFS
Race/ethnicity (non-Hispanic
white vs other)
Sex (female vs male)

29 (22)

1.466 0.631-3.405

.37

Age ($70 y vs ,70 y)

29 (22)

2.479 1.046-5.876

.04

ELN risk group (CN-AML vs
intermediate II)*

25 (18)

2.105 0.691-6.410

.19

Allelic ratio ($0.7 vs ,0.7)
(cutoff at median)

29 (22)

1.247 0.537-2.897

.61

CN, cytogenetically normal; ELN, European LeukemiaNet.
*No patients were ELN adverse.

20% (95% CI, 12%-34%), respectively. In univariable Cox regression
analysis of the FLT3-ITD population, only age $70 years was associated
with statistically significant differences in OS (hazard ratio [HR], 2.6;
95% CI, 1.2-5.5; P 5 .01), DFS (HR, 2.5; 95% CI, 1.05-5.9; P 5 .04),
and EFS (HR, 2.7; 95% CI, 1.3-5.5; P 5 .01) (Table 2; Figure 3).

Effect of allo-HCT
In this study, 22 patients (14 with FLT3-ITD [36%] and 8 with FLT3TKD [53%]) underwent allo-HCT; 18 of the transplants occurred
during CR1 (13 ITD and 5 TKD), 2 were performed in CR2 (2 TKD),
and 2 (1 ITD and 1 TKD) were performed during first relapse. The
median time to transplant for all patients was 164 days (range,
82-802). In an attempt to separate the effect of allo-HCT on patient
outcomes, we conducted a secondary sensitivity analysis in which
we censored subjects at the time of transplant (Figure 4A-B). After
censoring at the time of transplant, the 1-year rates of OS, DFS, and
EFS for the FLT3-ITD population were 52% (95% CI, 35%-76%),
40% (95% CI, 22%-71%), and 29% (95% CI, 16%-54%), respectively,
and 70% (95% CI, 45%-100%), 16% (95% CI, 3%-96%), and 11%
(95% CI, 2%-70%), respectively, for the FLT3-TKD population.
SORAFENIB FOR OLDER ADULTS WITH FLT3-MUTATED AML
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Figure 3. Kaplan-Meier curves for OS and EFS for FLT3-

A

ITD patients by age. (A) Patients aged 60 to 69 years. (B)
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FLT3 PIAs
To measure the degree of FLT3 inhibition occurring in vivo during
treatment with sorafenib, we measured the PIA for FLT3 in patient
plasma samples. The PIA is a surrogate for measuring target inhibition
by FLT3 inhibitors.28 In this study, the median result of this assay (the
percentage of baseline FLT3 autophosphorylation) in all patients was
6% of pretreatment baseline activity (range, 0-32) (n 5 25) on day 6
of induction, 2% (range, 0-24) (n 5 15) on day 15 of consolidation,
and 0% (range, 0-4) (n 5 6) on day 15 of maintenance, demonstrating
robust inhibition of FLT3 in vivo (Figure 5).

Discussion
In this paper, we describe the outcome of older adults with FLT3-mutated
AML treated with the combination of sorafenib and chemotherapy.
336

UY et al

Our data suggest an improvement for both OS and DFS and compare
favorably to the outcomes we observed for older FLT3-ITD–mutated
AML patients in previous CALGB clinical trials. The potential benefit
was primarily observed in individuals aged 60 to 69 years who had an
EFS and OS of 12.7 and 19.9 months, respectively, compared with 2.2
and 9.7 months for those $70 years. Moreover, toxicities were not
increased above those expected from a 713 regimen in older adults.
When comparing this study to historical CALGB data, there are several
important limitations in the interpretation of these results. As the role
of allo-HCT in this population evolves, the rates of transplantation for
both older adults and those with FLT3-mutated AML have increased.
Increased rates of transplantation combined with overall improvements
in reducing treatment-related mortality through better supportive care
24 JANUARY 2017 x VOLUME 1, NUMBER 5
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Figure 4. Sensitivity analysis for effect of allo-HCT. Kaplan-Meier curves for OS (A) and EFS (B) with and without censoring for allo-HCT by FLT3-mutated subgroups.

may partly account for the improvement in OS. However, when we
censored the analysis for transplantation and examined the EFS of the
population, these current results still compare favorably to the median
EFS of 0.4 years and 1-year EFS of 17% (95% CI, 9-26) observed in
earlier CALGB studies.11 This suggests that differences in outcome
remain and that the improved outcomes may be in part due to a
reduction in relapse from the addition of sorafenib.
Previous studies of FLT3 inhibitors in AML have had mixed results.
Agents such as midostaurin possess modest activity against FLT3
and are relatively nonspecific. As single agents, these drugs have
demonstrated only transient decreases in blast counts, which is
consistent with the finding that mutations in FLT3 occur relatively
late in leukemogenesis and frequently present in a subclone. In a
randomized phase 3 study of lestaurtinib conducted in relapsed and
refractory AML patients, measurement of FLT3 inhibition by PIA was
highly correlated with remission rate, but target inhibition on day 15
to ,15% of baseline activity was achieved in only 58% of patients
receiving lestaurtinib.30 In the current study, we observed a median
inhibition of .90%, which was sustained throughout induction and
consolidation. These earlier studies paved the way for more potent
24 JANUARY 2017 x VOLUME 1, NUMBER 5

inhibitors such as sorafenib and also support the rationale for
combining these agents with chemotherapy.
Recently, the Study Alliance Leukemia (SAL) in Germany reported
the results of 2 randomized, placebo-controlled, phase 2 studies
of sorafenib plus chemotherapy in newly diagnosed AML patients
regardless of FLT3 mutation status. In the SORAML study conducted
in younger adults (,60 years old), the median EFS improved from
9 months to 21 months in the sorafenib group, corresponding to a
3-year EFS of 22% in the placebo group vs 40% in the sorafenib
group (P 5 .013).24 This study aimed to transplant every eligible patient,
and there was no significant difference in OS. In addition, the benefit
was not restricted to the FLT3-ITD cohort. In contrast, in a second
trial designed for older adults (age .60 years), the addition of
sorafenib did not result in improvement in either EFS or OS.25 Notably, in
older adults, the combination of sorafenib and chemotherapy was
associated with an increased risk of early death (17% vs 7%). In
both studies, no differences were observed in outcome based on
FLT3 mutation status. However, the power to detect a difference in
the older adult study may be limited due to the relatively low numbers
of FLT3-ITD patients in that study (n 5 28).
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Several factors may account for the differences between our current
study and the SAL studies. First, the induction mortality of 9.3%
observed in the current study was less than the 17% observed in
the older adult SAL sorafenib study. In the older adult SAL study,
sorafenib was administered from day 10 of induction until 3 days
before the first day of the subsequent chemotherapy course, compared
with only on days 1 to 7 of induction in our study. It is possible that
prolonged exposure to sorafenib during induction chemotherapy may
account for the increased early mortality. Second, the beneficial effect in
the SORAML study was observed irrespective of the FLT3 genotype.
Recently, CALGB study 10603 (RATIFY) demonstrated that the
addition of midostaurin to standard chemotherapy for younger adults
(,60 years) with FLT3-mutated AML results in a significant survival
advantage over a placebo control in a phase 3 trial.31 Whether the
activity of sorafenib and other FLT3 inhibitors in AML is specifically due
to effects on FLT3 or on other kinase targets remains an open question.
Our understanding of the role of FLT3 mutations in AML continues
to evolve. As more comprehensive genomic studies are performed
on patients with AML, it has become clear that AML is a dynamic
disease with mutations variably distributed between founding
clones and subclones.32 Mutations in FLT3 frequently occur in a
subclone and also co-occur with other mutations such as NPM1
and DNMT3A. This can result in complex interactions that influence
clinical outcomes.33,34 Integrating genomic information both at
diagnosis and throughout therapy will be critical to understand the
impact of treatments such as FLT3 inhibitors.
In conclusion, our study demonstrates the feasibility of conducting
genotype-directed trials in the initial treatment of AML in the US
cooperative groups. We were able to deliver a rapid turnaround time,
with results returned to the treating physician within 48 hours, allowing
this study to be conducted without significantly delaying therapy.
Older adults have been an attractive patient group for the development
of novel therapies in AML due the historically poor outcomes and the
large need unmet by currently available therapies. With any new agent,
the potential for increased toxicity by adding the agent to a standard
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regimen may negate any clinical benefits. This appears to be particularly
true for older adults, for whom the safety margin for a 713 regimen is
low. Nevertheless, this study clearly adds to the growing literature
supporting the addition of tyrosine kinase inhibitors to chemotherapy in
AML and justifies further testing in a randomized phase 3 study.
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